Rasagiline derivatives combined with histamine H3 receptor properties

Khanfar, 2016, Multiple targeting approaches on histamine H3 receptor antagonists, Front Neurosci, 10, 1, 10.3389/fnins.2016.00201 Ramsay, 2018, A perspective on multi-target drug discovery and design for complex diseases, Clin Transl Med, 7, 3, 10.1186/s40169-017-0181-2 Proschak, 2019, Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds, J Med Chem, 62, 420, 10.1021/acs.jmedchem.8b00760 Connolly, 2014, Pharmacological treatment of Parkinson disease: a review, JAMA, 311, 1670, 10.1001/jama.2014.3654 Finberg, 1998, Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R (+)-N-propargyl-1-aminoindan (rasagiline) in the monkey, 279 Youdim, 2001, Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B, Br J Pharmacol, 132, 500, 10.1038/sj.bjp.0703826 Stocchi, 2015, Rasagiline for the treatment of Parkinson's disease: an update, Expert Opin Pharmacother, 16, 2231, 10.1517/14656566.2015.1086748 Sterling, 2002, Novel dual inhibitors of AChE and MAO derived from hydroxyl aminoindan and phenethylamine as potential treatment for Alzheimer's disease, J Med Chem, 45, 5260, 10.1021/jm020120c Youdim, 2013, Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and M30 derived from rasagiline, Exp Neurobiol, 22, 1, 10.5607/en.2013.22.1.1 Weinreb, 2012, Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment, Curr Drug Targets, 13, 483, 10.2174/138945012799499794 Affini, 2018, Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease, Eur J Med Chem, 148, 487, 10.1016/j.ejmech.2018.02.015 Ghamari, 2019, Histamine H3 receptor antagonists/inverse agonists: Where do they go?, Pharmacol Ther, 200, 69, 10.1016/j.pharmthera.2019.04.007 Hagenow, 2017, Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B, Sci Rep, 7, 40541, 10.1038/srep40541 Łażewska, 2018, 4-tert-Pentylphenoxyalkyl derivatives – histamine H3 receptor ligands and monoamine oxidase B inhibitors, Bioorg Med Chem Lett, 28, 3596, 10.1016/j.bmcl.2018.10.048 Weissman, 2005, Recent advances in ether dealkylation, Tetrahedron, 61, 7833, 10.1016/j.tet.2005.05.041 Williamson, 1851, About the theory of the formation of ethers, Ann Chem, 77, 37, 10.1002/jlac.18510770104 Tomasch, 2012, Novel chalcone-based fluorescent human histamine H3 receptor ligands as pharmacological tools, Front Syst Neurosci, 6, 1, 10.3389/fnsys.2012.00014 Sander, 2010, Acidic elements in histamine H3 receptor antagonists, Bioorg Med Chem Lett, 20, 1581, 10.1016/j.bmcl.2010.01.089 Sadek, 2014, Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties, Eur J Med Chem, 77, 269, 10.1016/j.ejmech.2014.03.014 Herzig, 2006, Hydroxy-1-aminoindans and derivatives: preparation, stability, and reactivity, J Org Chem, 71, 4130, 10.1021/jo052621m Sander, 2010, Metal-containing histamine H3 receptor ligands, Org Lett, 12, 2578, 10.1021/ol100419y Abdel-Magid, 1996, Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures, J Org Chem, 61, 3849, 10.1021/jo960057x Kottke, 2011, Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands, Eur J Pharmacol, 654, 200, 10.1016/j.ejphar.2010.12.033 Khanfar, 2018, Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine H3R ligands, Bioorg Med Chem, 26, 4034, 10.1016/j.bmc.2018.06.028 Carradori, 2015, New Frontiers in selective human MAO-B inhibitors: miniperspective, J Med Chem, 58, 6717, 10.1021/jm501690r Manley-King, 2011, Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues, Bioorg Med Chem, 19, 261, 10.1016/j.bmc.2010.11.028 Bautista-Aguilera, 2017, Multitarget-directed ligands combining cholinesterase and monoamine oxidase inhibition with histamine H3R antagonism for neurodegenerative diseases, Angew Chem Int Ed Engl, 56, 12765, 10.1002/anie.201706072